{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["EGFR", "anti-cancer", "cell lines", "indole", "ligand docking", "molecular modeling", "pyrazole", "pyrazolinyl-indole", "tyrosine kinase"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35742992", "DateCompleted": {"Year": "2022", "Month": "06", "Day": "27"}, "DateRevised": {"Year": "2022", "Month": "07", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "06", "Day": "11"}], "Language": ["eng"], "ELocationID": ["6548", "10.3390/ijms23126548"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "23", "Issue": "12", "PubDate": {"Year": "2022", "Month": "Jun", "Day": "11"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Synthesis and Anti-Cancer Activity of New Pyrazolinyl-Indole Derivatives: Pharmacophoric Interactions and Docking Studies for Identifying New EGFR Inhibitors.", "Abstract": {"AbstractText": ["Newly designed series of indole-containing pyrazole analogs, pyrazolinylindoles, were synthesized, and their structures were confirmed based on the spectral data of the <sup>1</sup>H NMR, <sup>13</sup>C NMR, and HR-MS analyses. Preliminary anti-cancer activity testings were carried out by the National Cancer Institute, United States of America (NCI, USA). Compounds HD02, HD05, and HD12 demonstrated remarkable cytotoxic activities against nine categories of cancer types based cell line panels which included leukemia, colon, breast, melanoma, lungs, renal, prostate, CNS, and ovarian cancer cell lines. The highest cytotoxic effects were exhibited by the compounds HD02 [1-(5-(1-H-indol-3-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-phenylethanone], HD05 [1-(3-(4-chlorophenyl)-5-(1H-indol-3-yl)-4,5-dihydro-1H-pyrazol-1-yl)-2-phenoxyethanone], and HD12 [(3-(4-chlorophenyl)-5-(1H-indol-3-yl)-4,5-dihydro-1H-pyrazol-1-yl)(pyridin-4-yl)methanone] against some of the 56 types of NCI-based cell lines in different panels. Compound HD05 showed the maximum range of cancer cell growth inhibitions against all categories of the cell lines in all nine panels. On average, in comparison to the referral standard, imatinib, at a dose level of 10 \u00b5M, the HD05 showed significant activity against leukemia in the range of 78.76%, as compared to the imatinib at 9% of cancer cells' growth inhibitions. Molecular docking simulation studies were performed in silico on the epidermal growth factor receptor (EGFR) tyrosine kinase, in order to validate the activity."]}, "AuthorList": [{"Identifier": ["0000-0002-7401-6254"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry and Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Unaizah 51911, Saudi Arabia."}], "LastName": "Khalilullah", "ForeName": "Habibullah", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Alwar College of Pharmacy, Alwar 302 023, Rajasthan, India."}], "LastName": "Agarwal", "ForeName": "Deepak K", "Initials": "DK"}, {"Identifier": ["0000-0002-6919-5489"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Maharishi Arvind College of Pharmacy, Jaipur 302 023, Rajasthan, India."}], "LastName": "Ahsan", "ForeName": "Mohamed J", "Initials": "MJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Centre for Molecular Cancer Research (CMCR), Vishnu Institute of Pharmaceutical Education and Research (VIPER), Narsapur 502 313, Telangana, India."}], "LastName": "Jadav", "ForeName": "Surender S", "Initials": "SS"}, {"Identifier": ["0000-0003-2896-6790"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Mohammed", "ForeName": "Hamdoon A", "Initials": "HA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Applied Sciences, Qassim University, Qassim 51452, Saudi Arabia."}], "LastName": "Khan", "ForeName": "Masood Alam", "Initials": "MA"}, {"Identifier": ["0000-0002-9250-100X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia."}], "LastName": "Mohammed", "ForeName": "Salman A A", "Initials": "SAA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia."}], "LastName": "Khan", "ForeName": "Riaz", "Initials": "R"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Indoles"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "8A1O1M485B", "NameOfSubstance": "Imatinib Mesylate"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "EGFR protein, human"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ErbB Receptors"}], "MeshHeadingList": [{"QualifierName": ["chemistry"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["metabolism"], "DescriptorName": "ErbB Receptors"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Imatinib Mesylate"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Indoles"}, {"QualifierName": [], "DescriptorName": "Leukemia"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": ["chemistry"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "World Health Organization.  [(accessed on 15 April 2022)].  Available online:  www.who.int/health-topics/cancer#tab=tab_1."}, {"Citation": "Schwartz R.N. Anemia in patients with cancer: Incidence, causes, impact, management, and use of treatment guidelines and protocols. Am. J. Health Pharm. 2007;64:S5\u2013S13. doi: 10.2146/ajhp060601.", "ArticleIdList": ["10.2146/ajhp060601", "17244886"]}, {"Citation": "Noolvi M.N., Patel H.M., Bhardwaj V., Chauhan A. Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: Search for anticancer agent. Eur. J. Med. Chem. 2011;46:2327\u20132346. doi: 10.1016/j.ejmech.2011.03.015.", "ArticleIdList": ["10.1016/j.ejmech.2011.03.015", "21458891"]}, {"Citation": "Aydemir N., Bilalo\u011flu R. Genotoxicity of two anticancer drugs, gemcitabine and topotecan, in mouse bone marrow in vivo. Mutat. Res. Toxicol. Environ. Mutagen. 2003;537:43\u201351. doi: 10.1016/S1383-5718(03)00049-4.", "ArticleIdList": ["10.1016/S1383-5718(03)00049-4", "12742506"]}, {"Citation": "Tok F., Abas B.\u0130., \u00c7evik \u00d6., Ko\u00e7yi\u011fit-Kaymak\u00e7\u0131o\u011flu B. Design, synthesis and biological evaluation of some new 2-Pyrazoline derivatives as potential anticancer agents. Bioorg. Chem. 2020;102:104063. doi: 10.1016/j.bioorg.2020.104063.", "ArticleIdList": ["10.1016/j.bioorg.2020.104063", "32663669"]}, {"Citation": "Wang H., Zheng J., Xu W., Chen C., Wei D., Ni W., Pan Y. A new series of cytotoxic pyrazoline derivatives as potential anticancer agents that induce cell cycle arrest and apoptosis. Molecules. 2017;22:1635. doi: 10.3390/molecules22101635.", "ArticleIdList": ["10.3390/molecules22101635", "PMC6151802", "28961210"]}, {"Citation": "Chouiter M.I., Boulebd H., Pereira D.M., Valent\u00e3o P., Andrade P.B., Belfaitah A., Silva A.M. New chalcone-type compounds and 2-pyrazoline derivatives: Synthesis and caspase-dependent anticancer activity. Future Med. Chem. 2020;12:493\u2013509. doi: 10.4155/fmc-2019-0342.", "ArticleIdList": ["10.4155/fmc-2019-0342", "32100558"]}, {"Citation": "Pecoraro C., Parrino B., Cascioferro S., Puerta A., Avan A., Peters G.J., Diana P., Giovannetti E., Carbone D. A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells. Molecules. 2021;27:19. doi: 10.3390/molecules27010019.", "ArticleIdList": ["10.3390/molecules27010019", "PMC8746667", "35011251"]}, {"Citation": "Carbone D., Vestuto V., Ferraro M.R., Ciaglia T., Pecoraro C., Sommella E., Cascioferro S., Salviati E., Novi S., Tecce M.F., et al. Metabolomics-assisted discovery of a new anticancer GLS-1 inhibitor chemotype from a nortopsentin-inspired library: From phenotype screening to target identification. Eur. J. Med. Chem. 2022;234:114233. doi: 10.1016/j.ejmech.2022.114233.", "ArticleIdList": ["10.1016/j.ejmech.2022.114233", "35286926"]}, {"Citation": "Song Y., Feng S., Feng J., Dong J., Yang K., Liu Z., Qiao X. Synthesis and biological evaluation of novel pyrazoline derivatives containing indole skeleton as anti-cancer agents targeting topoisomerase II. Eur. J. Med. Chem. 2020;200:112459. doi: 10.1016/j.ejmech.2020.112459.", "ArticleIdList": ["10.1016/j.ejmech.2020.112459", "32502865"]}, {"Citation": "Parmar S.S., Pandey B.R., Dwivedi C., Harbison R.D. Anticonvulsant activity and monoamine oxidase inhibitory properties of 1, 3, 5-trisubstituted pyrazolines. J. Pharm. Sci. 1974;63:1152\u20131155. doi: 10.1002/jps.2600630730.", "ArticleIdList": ["10.1002/jps.2600630730", "4850598"]}, {"Citation": "Budakoti A., Bhat A.R., Athar F., Azam A. Syntheses and evaluation of 3-(3-bromo phenyl)-5-phenyl-1-(thiazolo [4, 5-b] quinoxaline-2-yl)-2-pyrazoline derivatives. Eur. J. Med. Chem. 2008;43:1749\u20131757. doi: 10.1016/j.ejmech.2007.10.026.", "ArticleIdList": ["10.1016/j.ejmech.2007.10.026", "18068273"]}, {"Citation": "Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550\u20136565. doi: 10.1038/sj.onc.1204082.", "ArticleIdList": ["10.1038/sj.onc.1204082", "11426640"]}, {"Citation": "Manna F., Chimenti F., Fioravanti R., Bolasco A., Secci D., Chimenti P., Ferlini C., Scambia G. Synthesis of some pyrazole derivatives and preliminary investigation of their affinity binding to P-glycoprotein. Bioorg. Med. Chem. Lett. 2005;15:4632\u20134635. doi: 10.1016/j.bmcl.2005.05.067.", "ArticleIdList": ["10.1016/j.bmcl.2005.05.067", "16099651"]}, {"Citation": "Sim M.M., Ng S.B., Buss A.D., Crasta S.C., Goh K.L., Lee S.K. Benzylidene rhodanines as novel inhibitors of UDP-N-acetylmuramate/L-alanine ligase. Bioorg. Med. Chem. Lett. 2002;12:697\u2013699. doi: 10.1016/S0960-894X(01)00832-0.", "ArticleIdList": ["10.1016/S0960-894X(01)00832-0", "11844704"]}, {"Citation": "Turan-Zitouni G., Chevallet P., Kilic F.S., Erol K. Synthesis of some thiazolyl-pyrazoline derivatives and preliminary investigation of their hypotensive activity. Eur. J. Med. Chem. 2000;35:635\u2013641. doi: 10.1016/S0223-5234(00)00152-5.", "ArticleIdList": ["10.1016/S0223-5234(00)00152-5", "10906414"]}, {"Citation": "Bilgin A.A., Palaska E., Sunal R. Studies on the synthesis and antidepressant activity of some 1-thiocarbamoyl-3, 5-diphenyl-2-pyrazolines. Arzneimittelforschung. 1993;43:1041\u20131044.", "ArticleIdList": ["8267665"]}, {"Citation": "Sharma P.K., Kumar S., Kumar P., Kaushik P., Kaushik D., Dhingra Y., Aneja K.R. Synthesis and biological evaluation of some pyrazolylpyrazolines as anti-inflammatory\u2013antimicrobial agents. Eur. J. Med. Chem. 2010;45:2650\u20132655. doi: 10.1016/j.ejmech.2010.01.059.", "ArticleIdList": ["10.1016/j.ejmech.2010.01.059", "20171763"]}, {"Citation": "Dawane B.S., Konda S.G., Mandawad G.G., Shaikh B.M. Poly (ethylene glycol)(PEG-400) as an alternative reaction solvent for the synthesis of some new 1-(4-(4\u2032-chlorophenyl)-2-thiazolyl)-3-aryl-5-(2-butyl-4-chloro-1H-imidazol-5yl)-2-pyrazolines and their in vitro antimicrobial evaluation. Eur. J. Med. Chem. 2010;45:387\u2013392. doi: 10.1016/j.ejmech.2009.10.015.", "ArticleIdList": ["10.1016/j.ejmech.2009.10.015", "19896247"]}, {"Citation": "Yamaoka T., Ohba M., Ohmori T. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. Int. J. Mol. Sci. 2017;18:2420. doi: 10.3390/ijms18112420.", "ArticleIdList": ["10.3390/ijms18112420", "PMC5713388", "29140271"]}, {"Citation": "Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991;83:757\u2013766. doi: 10.1093/jnci/83.11.757.", "ArticleIdList": ["10.1093/jnci/83.11.757", "2041050"]}, {"Citation": "Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988;48:589\u2013601.", "ArticleIdList": ["3335022"]}, {"Citation": "Boyd M.R., Paull K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 1995;34:91\u2013109. doi: 10.1002/ddr.430340203.", "ArticleIdList": ["10.1002/ddr.430340203"]}, {"Citation": "Shoemaker R.H. The NCI 60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer. 2006;6:813\u2013823. doi: 10.1038/nrc1951.", "ArticleIdList": ["10.1038/nrc1951", "16990858"]}, {"Citation": "Blair J.A., Rauh D., Kung C., Yun C.H., Fan Q.W., Rode H., Zhang C., Eck M.J., Weiss W.A., Shokat K.M. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat. Chem. Biol. 2007;4:229\u2013238. doi: 10.1038/nchembio866.", "ArticleIdList": ["10.1038/nchembio866", "17334377"]}, {"Citation": "Holla B.S., Udupa K.V. Synthesis, spectral studies and biological activities of some N-bridged heterocycles derived from 3-arylaminomethyl-4-amino-5-mercapto-1,2,4-triazoles. Farmaco. 1992;47:305\u2013318. doi: 10.1002/chin.199408235.", "ArticleIdList": ["10.1002/chin.199408235", "1503594"]}, {"Citation": "Robinson M.W., Overmeyer J.H., Young A.M., Erhardt P.W., Maltese W.A. Synthesis and evaluation of indole-based chalcones as inducers of methuosis, a novel type of nonapoptotic cell death. J. Med. Chem. 2012;55:1940\u20131956. doi: 10.1021/jm201006x.", "ArticleIdList": ["10.1021/jm201006x", "PMC3314534", "22335538"]}, {"Citation": "Karthikeyan C., SHNarayana Moorthy N., Ramasamy S., Vanam U., Manivannan E., Karunagaran D., Trivedi P. Advances in chalcones with anticancer activities. Recent Pat. Anticancer Drug Discov. 2015;10:97\u2013115. doi: 10.2174/1574892809666140819153902.", "ArticleIdList": ["10.2174/1574892809666140819153902", "25138130"]}, {"Citation": "Faritha A., Nasser A.J.A., Ahamed A.P., Thajuddin N. Synthesis, characterization and biological activity of certain pyrazole derivatives. J. Chem. Pharm. Res. 2014;6:189\u2013193."}, {"Citation": "Karrouchi K., Radi S., Ramli Y., Taoufik J., Mabkhot Y.N., Al-Aizari F.A., Ansar M.H. Synthesis and Pharmacological Activities of Pyrazole Derivatives: A Review. Molecules. 2018;23:134. doi: 10.3390/molecules23010134.", "ArticleIdList": ["10.3390/molecules23010134", "PMC6017056", "29329257"]}, {"Citation": "Al-Anazi M., Al-Najjar B.O., Khairuddean M. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors. Molecules. 2018;23:3203. doi: 10.3390/molecules23123203.", "ArticleIdList": ["10.3390/molecules23123203", "PMC6321200", "30563058"]}, {"Citation": "Zaharevitz D.W., Holbeck S.L., Bowerman C., Svetlik P.A. COMPARE: A web accessible tool for investigating mechanisms of cell growth inhibition. J. Mol. Graph. Model. 2002;20:297\u2013303. doi: 10.1016/S1093-3263(01)00126-7.", "ArticleIdList": ["10.1016/S1093-3263(01)00126-7", "11858638"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "4", "Day": "24"}, {"Year": "2022", "Month": "5", "Day": "31"}, {"Year": "2022", "Month": "6", "Day": "4"}, {"Year": "2022", "Month": "6", "Day": "24", "Hour": "1", "Minute": "21"}, {"Year": "2022", "Month": "6", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "6", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "6", "Day": "11"}], "PublicationStatus": "epublish", "ArticleIdList": ["35742992", "PMC9223872", "10.3390/ijms23126548", "ijms23126548"]}}], "PubmedBookArticle": []}